Archive for the ‘Latest Research’ Category

4D Molecular Therapeutics Enrolling Patients in Natural History Study in Lead Clinical Program to Develop Gene Therapy Treatment for Choroideremia 

4DMT is accepting inquires from interested choroideremia (CHM) patients for their upcoming Natural History Study.  In partnership with the Choroideremia

In a letter published by the New England Journal of Medicine today, Dr. Robert Maclaren released positive long-term results from

        4D Molecular Therapeutics and the Choroideremia Research Foundation Partner to Develop Gene Therapy Treatment for Choroideremia

At Tübingen Department of Ophthalmology in Germany, the first gene therapy trial for Choroideremia patients began on January 13th. This

An announcement today by Spark Therapeutics brings the world one step closer toward a commercially available gene therapy treatment.  This

The Bascom Palmer Eye Institute at the University of Miami has announced the opening of a clinical trial using gene

The University of Alberta, in coordination with NightstaRx, have initiated a clinical trial for patients with Choroideremia using NightstaRx’s gene

PRESS RELEASE: London, 11 January 2015 – NightstaRx Ltd (“Nightstar”), the biopharmaceutical company specialising in bringing therapies for retinal dystrophies

Spark Therapeutics, the Philadelphia firm specializing in gene therapy treatments who just last week announced the start of the United States first